Noncompetitive excitatory amino acid receptor antagonists.
about
Magnesium administration provokes motor unit survival, after sciatic nerve injury in neonatal ratsNovel NMDA receptor modulators: an updateGlobal quantitative analysis of phosphorylation underlying phencyclidine signaling and sensorimotor gating in the prefrontal cortex.Prevention by NMDA receptor antagonists of the centrally-evoked increases of cardiac inotropic responses in rabbitsEffects of volatile solvents on recombinant N-methyl-D-aspartate receptors expressed in Xenopus oocytesEfficacy of tricaine methanesulfonate (MS-222) as an anesthetic agent for blocking sensory-motor responses in Xenopus laevis tadpolesDifferential role of N-methyl-D-aspartate receptor subunits 2A and 2B in mediating phencyclidine-induced perinatal neuronal apoptosis and behavioral deficits.Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat.Hippocampal synaptic plasticity and cognition.Essential role of NMDA receptor channel ε4 subunit (GluN2D) in the effects of phencyclidine, but not methamphetamine.Contractile properties and movement behaviour in neonatal rats with axotomy, treated with the NMDA antagonist DAP5.Ketamine and phencyclidine: the good, the bad and the unexpected.Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndromeNMDA receptor antagonist ketamine impairs feature integration in visual perceptionExcitatory amino acids contribute to the pathogenesis of perinatal hypoxic-ischemic brain injury.Neurotoxin-related research: from the laboratory to the clinic.Stimulation of noradrenaline release in human cerebral cortex mediated by N-methyl-D-aspartate (NMDA) and non-NMDA receptors.Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors.Effect of latent iron deficiency on GABA and glutamate neuroreceptors in rat brain.Acute N-methyl-D-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats.Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analysesPharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulatorsRecent advances in the physiology and pharmacology of pain: plasticity and its implications for clinical analgesia.Smithkline Beecham Prize for Young Psychopharmacologists: A review of the relationship between calcium channels and psychiatric disorders.Ketamine in pain management.Glutamate preferentially suppresses osteoblastogenesis than adipogenesis through the cystine/glutamate antiporter in mesenchymal stem cells.From muscle research to clinical applications: Do glutamate antagonists aid muscle recovery?Electrogenic uptake contributes a major component of the depolarizing action of L-glutamate in rat hippocampal slices.The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents.The Effects of NMDA Antagonists on Neuronal Activity in Cat Spinal Cord Evoked by Acute Inflammation in the Knee Joint.Effects of sigma ligands on the cloned mu-, delta- and kappa-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes.Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications.R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine.Pharmacological properties and SAR of new 1,4-disubstituted piperazine derivatives with hypnotic-sedative activity.A randomised, controlled study of peri-operative low dose s(+)-ketamine in combination with postoperative patient-controlled s(+)-ketamine and morphine after radical prostatectomy.Effects of phencyclidine on immediate early gene expression in the brain.NMDA Receptor Antagonist Ketamine Distorts Object Recognition by Reducing Feedback to Early Visual Cortex.Role of nitric oxide in regulating cerebrocortical oxygen consumption and blood flow during hypercapnia.Anaesthetics differentially modulate the trigeminocardiac reflex excitatory synaptic pathway in the brainstem.Neuronal protection and preservation of calcium/calmodulin-dependent protein kinase II and protein kinase C activity by dextrorphan treatment in global ischemia.
P2860
Q24800056-B0C8C47F-5E15-4EAD-B7AD-5AE3EBEAA522Q26849614-D5CDB97C-5E72-47F0-9A73-39DCB69AA9F3Q27319445-2C3CC10E-178E-4A75-9E0D-15A0B1C0E0FFQ27469178-ABD6F54E-B607-4128-86B7-A35E994CF7FBQ28344975-639B80FE-3469-411C-8AE7-35283E3C76F6Q28540235-C0AF2548-CDD0-4E1B-B528-57E3F6B7828DQ30478715-5537385E-9423-4B61-972A-332F93E49928Q33620557-5F553930-5D3E-40EA-A4C1-DC478AB82B87Q33727832-97CCED45-534F-4E53-AF90-A45E76EDA57EQ33742221-FB0498D3-E33C-4528-A551-F090BE86E68DQ34253638-63C5CD28-6E84-412A-8682-FF6F1E71A66AQ34480719-AE8F6045-0101-495D-8231-DC97304DB23FQ34554563-B4E52831-6621-4CA4-9B38-D1FEE993DB61Q35041262-47D445E4-8056-4275-8836-3502D0B41C77Q35246208-35BB810B-226B-4980-B092-6AB9887F219EQ35260764-D0CB427E-2ABC-4D7D-9C05-C7B78127A0D5Q35870548-C4729D85-2E06-4F66-AB59-C2768C271207Q36089680-CBCD21C9-FFFF-405B-9475-0EA5C3D02064Q36264549-8729C333-4FE6-4BA9-BAB5-9CD846983E8CQ36476509-FDE4EA71-6DBC-4D6D-B4E7-20373EA0CD5CQ37129398-37BDD74D-2AC9-4BF5-A687-1CEEB7D70656Q37978091-3CD906B9-3338-431F-983C-BAA8AF59497AQ37979202-25F53CFD-8914-478D-8F61-B7631489FE4AQ37980111-BD69D886-B3FE-4413-A2D6-90874BD23CE5Q38105649-12AF2674-2800-4C65-A9C2-A82F1124AA7DQ39666370-14B59423-C701-4354-8F51-A9B736BC8A82Q41145658-CA71A333-B2EB-4608-9795-1EDFB05FAEECQ42056596-F11C1425-910A-46DE-AAF2-FE814EC1CF04Q42153102-AD678A7A-2208-4BB7-964B-7CD2C49FC542Q42523382-C106CDC3-50D7-43D6-A076-D1A66B68E5EEQ42582270-BFB0EBF6-1F1F-4EAE-AA3E-0A3A91D23240Q42637057-F22CD560-A082-49C3-A400-D5A2DB33E852Q42713768-DB92FCEA-5076-40A4-AF87-30FDF6A79BB3Q43989511-21DC49E5-64F1-499B-B25C-AAB017EE7358Q44776821-F5BCF58E-6F0F-4841-9432-939EB017186AQ46246845-75989863-D888-4064-BFB2-C578BF9CC9AEQ47751121-7333F543-A44F-4004-83B7-9985129E6504Q48127519-63028DA9-5B26-482E-A847-1AC59B1EA991Q48229630-71CB1F14-1A8E-401E-A3DC-E808AADA92C1Q48264459-42F85B26-1C95-4947-B3A8-DCDE8488214E
P2860
Noncompetitive excitatory amino acid receptor antagonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Noncompetitive excitatory amino acid receptor antagonists.
@en
Noncompetitive excitatory amino acid receptor antagonists.
@nl
type
label
Noncompetitive excitatory amino acid receptor antagonists.
@en
Noncompetitive excitatory amino acid receptor antagonists.
@nl
prefLabel
Noncompetitive excitatory amino acid receptor antagonists.
@en
Noncompetitive excitatory amino acid receptor antagonists.
@nl
P1476
Noncompetitive excitatory amino acid receptor antagonists.
@en
P2093
P356
10.1016/0165-6147(90)90323-Z
P577
1990-02-01T00:00:00Z